A growing number of drugs are now available for the treatment of MM, including proteasome inhibitors (carfilzomib and isazomib), antibody-coupled drugs (daratumumab and elotuzumab), immunomodulatory drugs (thalidomide and lenalidomide), histone deacetylase inhibitors (panobinostat), completely novel drugs such as nuclear export protein inhibitor-1 (XPO-1, Swlinexor), and cellular immunotherapy (Abecma and Carvykti), all of which have shown significant anticancer efficacy in the clinical management of MM (14–16). Here, XPO1 is linked to Miyoshi myopathy.